Molecular markers of dihydroartemisinin-piperaquine resistance in northwestern Thailand.
DHA-PPQ
Pfcrt
Plasmodium falciparum
kelch13
plasmepsin-2
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
27 Nov 2022
27 Nov 2022
Historique:
received:
10
08
2022
accepted:
11
11
2022
entrez:
27
11
2022
pubmed:
28
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
Dihydroartemisinin-piperaquine (DHA-PPQ) combination therapy is the current first-line treatment for Plasmodium falciparum malaria in Thailand. Since its introduction in 2015, resistance to this drug combination has emerged in the eastern part of the Greater Mekong Subregion including the eastern part of Thailand near Cambodia. This study aimed to assess whether the resistance genotypes have arisen the western part of country. Fifty-seven P. falciparum-infected blood samples were collected in Tak province of northwestern Thailand between 2013 and 2019. Resistance to DHA was examined through the single nucleotide polymorphisms (SNPs) of kelch13. PPQ resistance was examined through the copy number plasmepsin-2 and the SNPs of Pfcrt. Among the samples whose kelch13 were successfully sequenced, approximately half (31/55; 56%) had mutation associated with artemisinin resistance, including G533S (23/55; 42%), C580Y (6/55; 11%), and G538V (2/55; 4%). During the study period, G533S mutation appeared and increased from 20% (4/20) in 2014 to 100% (9/9) in 2019. No plasmepsin-2 gene amplification was observed, but one sample (1/54) had the Pfcrt F145I mutation previously implicated in PPQ resistance. Kelch13 mutation was common in Tak Province in 2013-2019. A new mutation G533S emerged in 2014 and rose to dominance in 2019. PPQ resistance marker Pfcrt F145I was also detected in 2019. Continued surveillance of treatment efficacy and drug resistance markers is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Dihydroartemisinin-piperaquine (DHA-PPQ) combination therapy is the current first-line treatment for Plasmodium falciparum malaria in Thailand. Since its introduction in 2015, resistance to this drug combination has emerged in the eastern part of the Greater Mekong Subregion including the eastern part of Thailand near Cambodia. This study aimed to assess whether the resistance genotypes have arisen the western part of country.
METHODS
METHODS
Fifty-seven P. falciparum-infected blood samples were collected in Tak province of northwestern Thailand between 2013 and 2019. Resistance to DHA was examined through the single nucleotide polymorphisms (SNPs) of kelch13. PPQ resistance was examined through the copy number plasmepsin-2 and the SNPs of Pfcrt.
RESULTS
RESULTS
Among the samples whose kelch13 were successfully sequenced, approximately half (31/55; 56%) had mutation associated with artemisinin resistance, including G533S (23/55; 42%), C580Y (6/55; 11%), and G538V (2/55; 4%). During the study period, G533S mutation appeared and increased from 20% (4/20) in 2014 to 100% (9/9) in 2019. No plasmepsin-2 gene amplification was observed, but one sample (1/54) had the Pfcrt F145I mutation previously implicated in PPQ resistance.
CONCLUSIONS
CONCLUSIONS
Kelch13 mutation was common in Tak Province in 2013-2019. A new mutation G533S emerged in 2014 and rose to dominance in 2019. PPQ resistance marker Pfcrt F145I was also detected in 2019. Continued surveillance of treatment efficacy and drug resistance markers is warranted.
Identifiants
pubmed: 36437462
doi: 10.1186/s12936-022-04382-5
pii: 10.1186/s12936-022-04382-5
pmc: PMC9701414
doi:
Substances chimiques
piperaquine
A0HV2Q956Y
Antimalarials
0
artenimol
6A9O50735X
Artemisinins
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
352Subventions
Organisme : NIAID NIH HHS
ID : U19 AI089672
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
Sci Rep. 2021 Jun 28;11(1):13419
pubmed: 34183715
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29378723
Antimicrob Agents Chemother. 2015 Aug;59(8):4719-26
pubmed: 26014949
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Clin Infect Dis. 2016 Sep 15;63(6):784-791
pubmed: 27313266
Lancet Infect Dis. 2020 Dec;20(12):1470-1480
pubmed: 32679084
Parasit Vectors. 2022 Apr 12;15(1):130
pubmed: 35413937
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Lancet Infect Dis. 2017 May;17(5):491-497
pubmed: 28161569
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
Lancet Infect Dis. 2015 Jun;15(6):683-91
pubmed: 25877962
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0112121
pubmed: 34516247
Malar J. 2020 Jul 25;19(1):269
pubmed: 32711538
J Infect Dis. 2017 Aug 15;216(4):468-476
pubmed: 28931241
Lancet Infect Dis. 2016 Mar;16(3):357-65
pubmed: 26774243
Nat Genet. 2015 Mar;47(3):226-34
pubmed: 25599401
Antimicrob Agents Chemother. 2013 Feb;57(2):818-26
pubmed: 23208711
Int J Parasitol Drugs Drug Resist. 2019 Aug;10:20-27
pubmed: 31009824
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
N Engl J Med. 2008 Dec 11;359(24):2619-20
pubmed: 19064625
mBio. 2017 May 9;8(3):
pubmed: 28487425
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
Lancet. 2020 Apr 25;395(10233):1345-1360
pubmed: 32171078
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710
Malar J. 2019 Mar 7;18(1):60
pubmed: 30846002